Rapt Therapeutics (NASDAQ:RAPT) Receives $21.57 Consensus PT from Analysts

Key Points

• Rapt Therapeutics has received a consensus rating of "Moderate Buy" from analysts, with four hold ratings, two buy ratings, and one strong buy rating.
• Several research firms have different price targets for Rapt's stock, with UBS Group setting a target of $9.00 and Wells Fargo issuing a revised target of $38.00, down from $51.00.
• The company's stock price opened at $11.74, and its 12-month target price averages around $21.57 according to brokerages.

Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven analysts that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $21.5714.

Several research firms have recently commented on RAPT. HC Wainwright boosted their price target on shares of Rapt Therapeutics to $27.00 and gave the company a "buy" rating in a report on Thursday, July 10th. Wall Street Zen downgraded shares of Rapt Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Lifesci Capital raised shares of Rapt Therapeutics to a "strong-buy" rating and set a $31.00 price objective on the stock in a report on Tuesday, July 22nd. Wells Fargo & Company reiterated an "overweight" rating and issued a $38.00 target price (down from $51.00) on shares of Rapt Therapeutics in a research note on Friday, August 8th. Finally, UBS Group set a $9.00 target price on shares of Rapt Therapeutics and gave the company a "neutral" rating in a research note on Tuesday, August 12th.

Rapt Therapeutics Stock Down 7.8%

RAPT traded down $0.91 during trading on Friday, hitting $10.82. The company's stock had a trading volume of 36,230 shares, compared to its average volume of 113,164. Rapt Therapeutics has a one year low of $5.67 and a one year high of $26.56. The firm has a market cap of $178.96 million, a PE ratio of -0.76 and a beta of 0.01. The business's 50 day simple moving average is $9.75 and its 200-day simple moving average is $8.85.

Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.04). Equities research analysts expect that Rapt Therapeutics will post -2.14 EPS for the current fiscal year.

Institutional Trading of Rapt Therapeutics

Institutional investors have recently made changes to their positions in the company. Simplicity Wealth LLC acquired a new stake in shares of Rapt Therapeutics in the 1st quarter valued at about $25,000. Exchange Traded Concepts LLC lifted its holdings in shares of Rapt Therapeutics by 27.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 113,738 shares of the company's stock valued at $139,000 after buying an additional 24,662 shares during the period. Callan Family Office LLC increased its stake in Rapt Therapeutics by 53.9% in the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock valued at $109,000 after purchasing an additional 31,287 shares in the last quarter. Comerica Bank increased its position in Rapt Therapeutics by 53.9% during the first quarter. Comerica Bank now owns 89,327 shares of the company's stock worth $109,000 after buying an additional 31,287 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Rapt Therapeutics by 4.9% during the fourth quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock worth $1,133,000 after buying an additional 33,758 shares in the last quarter. 99.09% of the stock is owned by institutional investors and hedge funds.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.